A new therapeutic approach for Parkinson's disease: dual targeting of alpha-Synuclein aggregation and microglial function by the novel immunomodulator 3-Monothiopomalidomide
Maria Francesca Palmas, Khosro Aminzadeh, Matteo Runfola, Pathik Parekh, Clara Porcedda, David Tweedie, Luca Casula, Maria Cristina Cardia, Jacopo Marongiu, Michela Etzi, Francesco Lai, Marcello Serra, Augusta Pisanu, Valeria Sogos, Alfonso De Simone, , Anna Rosa Carta
This paper evaluates 3MP, a novel immunomodulator, showing it reduces alpha-Synuclein aggregation and microglial inflammation in vitro and in vivo, offering a dual-target therapeutic approach for Parkinson's disease.
bioRxiv · Mar 30, 2026 · PreprintNeuroscience